Literature DB >> 21722540

Optimised diagnosis and treatment of necrotizing external otitis is warranted.

Kirse Bock1, Therese Ovesen.   

Abstract

INTRODUCTION: Necrotizing external otitis (NEO) is a devastating and life-threatening infection in the external auditory canal and the temporal bone. The aim of this paper is to evaluate the diagnostics and treatment of NEO and to recommend new guidelines.
MATERIAL AND METHODS: Eleven patients were retrospectively enrolled under the code DH609 otitis externa without specification from 1 January 2000 to 31 December 2009. Records were reviewed to register: age, symptoms, clinical findings, comorbidity, imaging, microbiology and treatment.
RESULTS: The median age was 75 years and the median time of therapy at the hospital was 6.3 months. All patients belonged to a risk group. A diagnostic delay was found resulting in further progression of the disease. In contrast to current international recommendations, the treatment consisted mostly of local antibiotics in combination with surgery. All patients survived, but most patients were left with hearing loss and psychiatric problems.
CONCLUSION: A greater awareness of diagnostic criteria and a shift from local antibiotics to prolonged systemic monotherapy with ciprofloxacin in accordance with international concepts is recommended. Surgery should be left for extensive and refractory cases only. A list of diagnostic criteria and treatment guidelines is presented. FUNDING: Not relevant. TRIAL REGISTRATION: Not relevant.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21722540

Source DB:  PubMed          Journal:  Dan Med Bull        ISSN: 0907-8916


  2 in total

1.  Malignant otitis externa in a healthy non-diabetic patient.

Authors:  Xiao-Long Liu; Hong Peng; Ting-Ting Mo; Yong Liang
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-08-02       Impact factor: 2.503

2.  Technetium-99m (⁹⁹mTc)-labelled sulesomab in the management of malignant external otitis: is there any role?

Authors:  Francesco Galletti; Giovanni Cammaroto; Bruno Galletti; Natale Quartuccio; Francesca Di Mauro; Sergio Baldari
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-02-18       Impact factor: 2.503

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.